Re: Non-Antibacterial Tetracyclines Demonstrate Disease Protection in Preclinical

[Guest guest]

This is really exciting! Perhaps we will end up with a cocktail of MS

disease modifiers like LDN & tetracycline that can be taken orally,

w/o bad side effects.

I take it from this article this compound is not avaialable now?

Could it be compounded?

> This new, proprietary class of non-antibacterial

tetracycline compounds will avoid the negative consequences

associated with long-termantibiotic use and will not further

contribute to the development of antibiotic resistance.

[Guest guest]

Tetracycline is a very powerful antibiotic that does a number on the

good bacteria of the bowel so if this is the answer?? then take lots of

acidophilus with it or be prepared for a huge overgrowth of

yeast.....which they think can also cause MS??

On 28-Oct-04, at 11:29 AM, redtruck99 wrote:

>

> This is really exciting! Perhaps we will end up with a cocktail of MS

> disease modifiers like LDN & tetracycline that can be taken orally,

> w/o bad side effects.

>

> I take it from this article this compound is not avaialable now?

> Could it be compounded?

>

> > This new, proprietary class of non-antibacterial

> tetracycline compounds will avoid the negative consequences

> associated with long-termantibiotic use and will not further

> contribute to the development of antibiotic resistance.

>

>

>

>

>

>

>

[Guest guest]

This actually is good news. Minocycline (a member of the

tetracycline family) is believed to be effective against MS by being

inhibiting certain enzymes called MMPs. A small phase 1 trial has

been completed; I can't find the details, but I believe they were

very successful (lesions reduced, no relapses for RRMS folks). The

problem with minocycline is that it's an antibiotic, and so kills

good bacteria you would like to keep.

This new tetracycline variant is minocycline without the antibiotic

properties, but with the MMP inhibiting characteristics. So it could

be a good thing. No idea as to when they would test it, or what the

timeline looks like for approval and release to the public.

>

> >

> > This is really exciting! Perhaps we will end up with a cocktail

of MS

> > disease modifiers like LDN & tetracycline that can be taken

orally,

> > w/o bad side effects.

> >

> > I take it from this article this compound is not avaialable now?

> > Could it be compounded?

> >

> > > This new, proprietary class of non-antibacterial

> > tetracycline compounds will avoid the negative consequences

> > associated with long-termantibiotic use and will not further

> > contribute to the development of antibiotic resistance.

> >

> >

> >

> >

> >

> >

> >

[Guest guest]

Please note that it says "non-antibacterial", this is an attempt to gain the benefit without the side effect of killing the gut flora...

----- Original Message -----

From: Kathy Huget

low dose naltrexone

Sent: Thursday, October 28, 2004 12:39 PM

Subject: Re: [low dose naltrexone] Re: Non-Antibacterial Tetracyclines Demonstrate Disease Protection in Preclinical

Tetracycline is a very powerful antibiotic that does a number on the good bacteria of the bowel so if this is the answer?? then take lots of acidophilus with it or be prepared for a huge overgrowth of yeast.....which they think can also cause MS??On 28-Oct-04, at 11:29 AM, redtruck99 wrote:

This is really exciting! Perhaps we will end up with a cocktail of MS disease modifiers like LDN & tetracycline that can be taken orally, w/o bad side effects.I take it from this article this compound is not avaialable now? Could it be compounded?> This new, proprietary class of non-antibacterialtetracycline compounds will avoid the negative consequencesassociated with long-termantibiotic use and will not furthercontribute to the development of antibiotic resistance.

[Guest guest]

This is very good and very promising. If you read anything of what

Dr. Blaylock, retired neurosurgeon has written, then you

could see that excitotoxins cause central nervous system damage.

One of the major sources of these excitototoxins (glutamate and

quinolnic acid) is the microglia, which are in a state of intense

activation in active MS. By blocking the activity of the microglia,

oligodendrocyte survival is increased and re-myelination can take

place. There has been a lot of anecdotal success with minocycline,

and the presumed etiology was therefore thought to be infectious. I

like Blaylock's explanation better. By developing a

tetracycline-like drug, then the benefit could be present without

the side effect of bacterial resistance from long-term antibiotic

use.

> Non-Antibacterial Tetracyclines Demonstrate Disease Protection

in

> Preclinical Studies

>

> Neuroscience Annual Meeting

>

> BOSTON, Oct. 27 /PRNewswire/ – Paratek Pharmaceuticals, Inc.

> announcedresults of preclinical studies demonstrating that a new

> class of compounds,orally available non-antibacterial

tetracyclines,

> has shown promising activityin a preclinical animal model of

multiple

> sclerosis (MS). Affecting approximately two million people

worldwide,

> MS is a chronic, inflammatorycondition of the nervous system and

the

> most common non-traumatic neurologicaldisease in young adults.

>

> Dr. McKenney, a Paratek scientist, will present the

findings

> during an oral presentation at 2:30 p.m. PST (5:30 p.m.EST) today

at

> Neuroscience 2004, the Society for Neuroscience's 34th

AnnualMeeting

> in San Diego. For the first time, Paratek is presenting data

showing

> that its non-antibacterial tetracycline compounds in a

preclinical

> model of MS have efficacy comparable to minocycline, an

antibiotic

> also in the tetracyclinefamily. A previous clinical study

directed by

> Dr. Luanne Metz at theUniversity of Calgary has demonstrated

disease

> protection in MS patients treated with minocycline.

Unfortunately,

> long-term treatment with minocycline or any other broad-spectrum

> antibiotic causes many patients to experience intolerability

related

> to antibiotic side effects.

>

> In today's presentation, Paratek will report that three

> non-antibacterial tetracycline compounds, with different

structures,

> demonstrated activity in reducing limb paralysis in the pre

clinical

> EAE (Experimental Autoimmune Encephalomyelitis) model of MS.

These

> compounds have no detectable antibacterial activity. Paratek

> Pharmaceuticals, Inc. and Serono (NYSE: SRA; virt-x: SEO)

announced

> today that they have entered into an agreement to discover,

developand

> commercialize an orally available disease-modifying treatment

for

> multiplesclerosis (MS). The agreement covers the compounds for

which

> Dr. McKenney presents data today. Stuart Levy, Paratek's Vice

> Chairman, Chief Scientific Officer andCo-Founder, commented, " The

> clinical research community has long regarded a pill for MS as an

> ultimate goal, but so far attempts to develop a safe, feasible,

> orally available drug candidate have failed. Our team has

> successfully modified the tetracycline molecule, keeping the core

> structure that confers anti-MS activity while removing portions

of

> the molecule with antibacterial effects. This represents an

exciting

> advance not only for MS, but potentially for many other

> inflammation-related disease areas. " Dr. Draper,

Associate

> Director at Paratek, stated, " Paratek has developed world-class

> expertise in modifying the tetracycline class, which has a 30-

year

> track record in the marketplace and a favorable, well-documented

> safety profile. This new, proprietary class of non-antibacterial

> tetracycline compounds will avoid the negative consequences

> associated with long-termantibiotic use and will not further

> contribute to the development of antibiotic resistance. We

believe

> that these highly active, orally available compounds will also

prove

> to be well tolerated for MS, and we are very proud of this

> accomplishment. "

>

> About Multiple Sclerosis Multiple sclerosis is a chronic,

> inflammatory condition of the nervous system and is the most

common

> non-traumatic neurological disease in young adults. Multiple

> sclerosis may affect approximately two million people worldwide.

> While symptoms can vary, the most common symptoms of multiple

> sclerosis include blurred vision, numbness or tingling in the

limbs

> and problems with strength and coordination. The relapsing forms

of

> multiple sclerosis are the most common.

>

> About Paratek Pharmaceuticals Paratek Pharmaceuticals, Inc. is

engaged

> in the discovery and commercialization of new therapeutics that

treat

> serious and life-threatening diseases, with a particular focus on

the

> growing worldwide problem of antibiotic resistance. Paratek's

lead

> programs are advancing novel compounds that can circumvent or

block

> bacterial resistance, as well as drugs that canprevent infection

by

> interfering with Multiple Adaptational Response (MAR) mechanisms

in

> bacteria. Out of these efforts, Paratek has discovered a newclass

of

> antibiotics, the aminomethylcyclines that target the need for new

and

> potent antibacterials to overcome the problem of rapidly growing

> bacterial resistance. The Company's lead antibiotic clinical

> candidate, BAY 73-7388,the first product from this class, is

being

> developed in a collaborative partnership with Bayer HealthCare AG

for

> the treatment of serious infections. Outside the antibacterial

> therapeutic area, Paratek has also established an internal effort

to

> exploit its novel families of compounds and their unique

mechanism of

> action in selected anti-inflammatory and neurodegenerative

conditions.

> Paratek has an active chemical synthesis effort to produce novel

and

> diverse small molecules, with the goal of developing

> non-antibacterial products with improved activity in serious

diseases

> based upon a growing body of clinical and basic research

supporting

> this approach. Paratek is privately held and headquartered in

Boston,

> Massachusetts, USA.

> For more information, visit Paratek's website at

> http://www.paratekpharm.com.